NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023

04 May 2023
www.biospace.com
Phase 2
Oral presentation sharing significant phase 2 results of Mazindol ER in Adults with Narcolepsy Type 1 and Type 2 Five abstracts demonstrating NLS focus on and investment in hypersomnia disorders and rare and complex neurologic diseases ZURICH, SWITZERLAND / ACCESSWIRE / May 4, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will present clinical data for the lead compound, Mazindol ER, as well as preclinical data on its pipeline compound, NLS-4, at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), which is being held from June 3 - 7, 2023, in Indianapolis. NLS Pharmaceutics' will present four posters highlighting data from the recently completed Phase 2 multi-center U.S. clinical study evaluating Mazindol ER, a triple monoamine reuptake inhibitormonoamine reuptake inhibitor and partial Orexin-2 Receptor agonistOrexin-2 Receptor agonist, in adult patients suffering from narcolepsy that met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. In addition, NLS will present preclinical data on NLS-4, an alpha-1 adrenergic receptor agonistalpha-1 adrenergic receptor agonist, a wake-promoting agent associated with fatigue recovery and hypersomnolence reduction. "As previously announced, once-daily Mazindol ER shows potential to meet the unmet needs of narcolepsy patients." commented Dr. George Apostol, Chief Medical Officer, adding "We look forward to sharing extensive data from our Phase 2 clinical trial as well as data from our lead pipeline compound, NLS-4, in Indianapolis at SLEEP 2023 as we prepare to commence our Phase 3 program for Mazindol ER this summer." Details of NLS Pharmaceutics' Research Presentations are as follows: Oral Presentation: Title: Clinician and Patient Global Impression in a Phase 2 Study of Mazindol (NLS-1021) in Adults with Narcolepsy Type 1 and Type 2 Date: June 5, 2023, 11:15 - 11:30am EDT Oral Presentation: Russel Rosenberg, PhD, Chief Science Officer & CEO, NeuroTrials Research Authors: Richard Bogan, Thomas Stern, Bruce Corser, Daniel Garber, Jennifer Franco, Eric Konofal, George Apostol, Anne Marie Morse, Clete Kushida, Michael Thorpy, Russell Rosenberg Mazindol Posters: Title: Functional Outcomes of Sleep Questionnaire in a phase 2 study of mazindol ER in narcolepsy Date: June 6, 2023, 12:00 - 1:15pm Authors: Richard Bogan, Thomas Stern, Bruce Corser, Daniel Garber, Jennifer Franco, Eric Konofal, George Apostol, Anne-Marie Morse, Russell Rosenberg, Michael Thorpy, Clete Kushida Poster Board Number: 327 Title: Long-term efficacy on cataplexy attacks and excessive daytime sleepiness in open-label extension study (NLS-1022) of mazindol ER Date: June 6, 2023, 12:00 - 1:15pm Authors: Thomas Stern, Bruce Corser, Daniel Garber, Richard Bogan, Jennifer Franco, Eric Konofal, George Apostol, Russell Rosenberg, Anne-Marie Morse, Michael Thorpy, Clete Kushida Poster Board Number: 329 Title: A four-week randomized, double-blind, placebo-controlled, phase 2 study of mazindol ER in the treatment of narcolepsy Date: June 6, 2023, 5:00 - 6:00pm Authors: Bruce Corser, Daniel Garber, Thomas Stern, Richard Bogan, Eric Konofal, Jennifer Franco, George Apostol, Anne Marie Morse, Russell Rosenberg, Clete Kushida, Michael Thorpy Poster Board Number: 328 NLS-4 Posters: Title: Effects of NLS-4 (Lauflumide) and modafinil in a rat model of circadian rhythm and chronic severe fatigue Date: June 5, 2023, 12:00 - 1:15pm Authors: Jean-Charles Bizot, Fabienne Massé, Julie Combeau, Norinne Lacerda-Queiroz, Sabrina David, Laurent Benel, George Apostol, Eric Konofal Poster Board Number: 57 About NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit . For additional information: Marianne Lambertson (investors & media) NLS Pharmaceutics Ltd. +1 239.682.8500 ml@nls-pharma.com SOURCE: NLS Pharmaceutics AG View source version on accesswire.com:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.